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Objective. Adiponectin has anti-atherogenic and anti-inﬂammatory properties. We investigated the inﬂuence of adiponectin on
glucose tolerance status, adiposity and cardiovascular risk factors (CVRFs). Design and Patients. Study consisted of 107 subjects:
55withnormalglucosetolerance(NGT)and52withimpairedglucoseregulation(IGR)whoweredividedintotwogroups:24sub-
jects with impaired fasting glucose (IFG Group) and 28 patients with type 2 diabetes mellitus (DM Group). In additional analysis,
study participants were divided into two groups, according to CVRFs: low and high risk. Measurements: Patients were evaluated
for glucose, HbA1C, insulin, lipids, CRP, HOMA-IR and adiponectin. Measurements. Patients were evaluated for glucose, HbA1C,
insulin, lipids, CRP, HOMA-IR and adiponectin. Results. Adiponectin was signiﬁcantly higher in NGT group than in IFG (P =
0.003) and DM (P = 0.01) groups. Adiponectin was signiﬁcantly, positively associated with HDL and inversely associated with
glucose,HbA1c,ALT,AST,TG,HOMA-IR.PatientswithhigherCVRFsloadhavelesseradiponectincomparedtopatientswithlow
cardiovascular risk P<0.0001). Adiponectin was inversely associated with the number of risk factors (r =− 0.430, P = 0.0001).
Conclusions. Circulating adiponectin was signiﬁcantly lower in subjects with diﬀerent degree of IGR compared to subjects with
normalglucosehomeostasis.Adiponectinwassigniﬁcantlylowerinhighriskgroupthanlowriskgroupanddecreasedconcurrent-
ly with increased number of CVRFs.
1.Introduction
Adiponectin, a collagen-like protein speciﬁcally and highly
expressed in human adipose cells, plays an important role in
insulin sensitivity, inﬂammation, lipid metabolism, and ath-
erogenesis [1–3]. Low plasma adiponectin levels are signif-
icantly correlated with endothelial dysfunction, increased
intima media thickness, and progression of coronary artery
calciﬁcation independently of other cardiovascular risk fac-
tors [4–6]. Plasma adiponectin levels are reduced not only
among obese patients but also in disease states frequently
associatedwithobesity,suchastype2diabetes,hypertension,
metabolic syndrome, and coronary artery disease [7–9]. Al-
together, these data suggest that adiponectin may mediate
its eﬀects via obesity-independent mechanisms, but whether
obesity per se or other pathways play a regulatory role is un-
clear and deserves further evaluation. The present study was
designed to assess the relation between plasma adiponectin
levels to glucose tolerance status, adiposity, and cardiovascu-
lar risk factors (CVRFs) load.
2. Methods
The study group consisted of 107 Caucasian subjects, (67
females, mean age 56.4 ± 10.0 years) who were recruited
from the outpatient metabolic clinic and evaluated for the
study. The study participants were divided into three groups
accordingtoglucosetolerancestatus:55withnormalglucose2 Experimental Diabetes Research
Table 1: Clinical characteristics of study patients by glucose tolerance status.
Variables NGT group
n = 55
IFG group
n = 24
DM group
n = 28
Female/male 39/16 7/17 17/11
Age (y) 55.7 ±9.55 8 .8 ±9.65 5 .9 ±11.3
BMI (kg/m2)3 3 .3 ±6.53 2 .9 ±6.83 1 .6 ±6.2
Current smokers, n (%) 7 (13%) 3 (8%) 3 (11%)
Hypertension, n (%) 28 (52%) 10 (42%) 15 (54%)
Dyslipidemia, n (%) 24 (44%) 12 (50%) 17 (61%)
Systolic blood pressure (mmHg) 131.5 ±18.4 134.7 ±18.7 134.9 ±19.6
Diastolic blood pressure (mmHg) 73.4 ±14.17 6 .5 ±12.17 6 .0 ±9.6
Fasting glucose (mg/dL) 89.5 ±7.3 109.4 ±7.6∗ 156.0 ±53.5∗
HBAIC (%) 5.7 ±0.45 .9 ± 0.5∗ 8.0 ±2.1∗
HDL-cholesterol (mg/dL) 56.6 ±21.34 7 .6 ± 13.4∗ 45.9 ±18.3∗
Triglycerides (mg/dL) 119.9 ±59.4 150.6 ±62.0∗ 195.3 ±158.4∗
Hs-CRP (mg/dL) 0.9 ±0.40 .7 ±1.20 .9 ±1.1
ALT (mg/dL) 26.2 ±12.83 0 .9 ±16.23 3 .6 ±29.1∗
AST (mg/dL) 22.9 ±7.82 7 .5 ±8.62 8 .0 ±18.0
Fasting insulin (IU/mL) 12.6 ±7.22 6 .0 ± 20.1∗ 18.8 ±16.0∗
HOMA-IR 2.8 ±1.77 .2 ± 5.7∗ 7.2 ±7.6∗
Adiponectin (ng/mL) 12597.2 ±7237.6 7567.5 ± 4193.5∗ 7484.2 ±4563.9∗
∗P value versus NGT group (signiﬁcant at the 0.05 level).
tolerance (NGT Group), 24 subjects with impaired fasting
glucose (IFG Group), and 28 patients with type 2 diabetes
mellitus (DM Group).
The cutoﬀ f o rI F Gw a sd e ﬁ n e da sF B G= 100 − 125mg/
dL, according to current ADA criteria [10].
In additional analysis study, participants were divided
into two groups, according to CVRFs: low- and high-risk
subjects. Cardiovascular risk factors were deﬁned using the
ATP III deﬁnition and included the following disorders: hy-
pertriglyceridemia (≥150mg/dL and/or pharmacological
treatment), low HDL cholesterol level (<40mg/dL in men
and <50mg/dL in women), high blood pressure (systolic
bloodpressure ≥130mmHgand/ordiastolicBP ≥85mmHg
and/or pharmacological treatment), and elevated plasma
glucose ≥100mg/dL and/or pharmacological treatment).
Obesity was deﬁned using the World Health Organization
criteria (BMI ≥ 30kg/m2). According to the above-mention-
ed CVRFs, the high-risk group included patients with three
or more CVRFs (n = 55), whereas low risk had two or less
CVRFs (n = 52).
2.1. Biochemical Parameters. Blood sampling for full chem-
istry and metabolic parameters, including fasting glucose,
HbA1C,c-peptide,insulin,lipidsproﬁle,ﬁbrinogen,hs-CRP,
and plasma adiponectin, will be performed. Adiponectin
will be determined by a commercial sandwich enzyme im-
munoassaytechnique,R&DSystems,Minneapolis,MN,USA
(catalog number DRP300) with 2.8% intra-assay and 6.5%
interassay variability.
Insulin resistance and β-cell function was estimated
usinghomeostasismodelassessment.Homeostasismodelas-
sessment-insulinresistance(HOMA-IR)willbecalculatedby
the following formula: fasting plasma insulin (mU/mL) ×
fasting plasma glucose (mg/dL)/405 [11], HOMA for β-cell
function (HOMA-β) as follows: 20 × fasting plasma insulin
(mU/mL)/fasting plasma glucose (mmol/L)−3.5.
2.2. Statistical Analysis. Analysis of data was carried out us-
ing SPSS 9.0 statistical analysis software (SPSS Inc., Chicago,
IL, USA, 1999). For continuous variables, such as hemo-
dynamic and biochemistry measures, descriptive statistics
were calculated and reported as mean ± standard deviation.
Distributions of continuous variables were assessed for
normality usingtheKolmogorov-Smirnov test(cutoﬀat P =
0.01). Associations between continuous variables with ap-
proximately normal distributions including anthropometric,
metabolic, and hemodynamic parameters were described
usingPearson’scorrelationcoeﬃcients.Associationsbetween
continuous variables with distributions signiﬁcantly deviat-
ing from normal were described using Spearman’s rho coe-
ﬃcients. All tests are twosided and considered signiﬁcant
at P<0.05.
3. Results
Demographic and clinical characteristics of the study groups
accordingtoglucosetolerancestatusarepresentedinTable 1.
As can be seen, all groups were similar in terms of age,
BMI,andpresenceofconcomitantcardiovascularriskfactors
such as hypertension, dyslipidemia, and smoking. Fasting
glucose diﬀered signiﬁcantly between each group and every
other group, lowest in NGT subjects and highest in patients
with DM, as expected. HOMA-IR as well as fasting insulin
was signiﬁcantly lower in NGT group than in IFG and DMExperimental Diabetes Research 3
Table 2: Correlations.
Circulating adiponectin
Age r-value 0.295(∗∗)
P value 0.002
BMI r-value −0.008
P value 0.931
AST r-value −0.279(∗∗)
P value 0.004
ALT r-value −0.348(∗∗)
P value 0.0001
HDL-cholesterol r-value 0.418(∗∗)
P value 0.0001
LDL-cholesterol r-value 0.128
P value 0.206
Triglycerides r-value −0.453(∗∗)
P value 0.0001
Hs-CRP r-value −0.169
P value 0.085
Fasting glucose r-value −0.375(∗∗)
P value 0.0001
HbA1C r-value −0.328(∗∗)
P value 0.001
Fasting insulin r-value −0.537(∗∗)
P value 0.0001
HOMA-IR r-value −0.623(∗∗)
P value 0.0001
∗∗Correlation is signiﬁcant at the 0.01 level (2-tailed).
groups, but not diﬀerent between IFG and DM groups. Ad-
ditionally, signiﬁcant intergroup diﬀerences were detected
for HDL-cholesterol and triglycerides.
Adiponectin was signiﬁcantly higher in NGT group than
in IFG (P = 0.003) and DM (P = 0.01) groups. A diﬀerence
in plasma adiponectin levels between IFG and DM groups
was not detected.
As shown in Table 2, adiponectin was signiﬁcantly, posi-
tively associated with HDL, signiﬁcantly inversely associ-
ated with glucose, HbA1c, ALT, AST, triglycerides, insulin,
HOMA-IR, and marginally inversely associated with CRP.
No association between adiponectin and BMI was observed
(r =− 0.008, P = 0.931). Multiple regression models which
were arrived at using a backward, stepwise approach were
performed to identify variables independently associated
with plasma adiponectin levels. In this model, adiponectin
wassigniﬁcantlyinverselyassociatedwithHbA1C(standard-
ized beta =− 0.385, P = 0.009) and ALT (standardized
beta =− 0.453, P = 0.040). The overall model is signiﬁcant
(P<0.0001) and explains 38.2% of variability in plasma adi-
ponectin levels.
In additional statistical analysis, the study participants
were divided into two groups according to the presence of
CVRFs: low-risk and high-risk. As can be seen in Table 3,a g e
and BMI were not diﬀerent between low-risk and high-risk
patients. High risk-subjects had a median of 3 CVRFs (range
3–4),whilelow-risksubjectshadamedianof2CVRFs(range
0–2). Systolic and diastolic blood pressure as well as fasting
glucose, HbA1C, fasting insulin, HOMA-IR, triglycerides,
AST, and LDL-cholesterol were signiﬁcantly higher and
HDL-cholesterol signiﬁcantly lower in high versus low-risk
patients. Plasma adiponectin levels were signiﬁcantly lower
in high-risk group compared to low-risk subjects (6755.6 ±
3492.2 versus 13701.1 ±7051.5ng/mL,P<0.0001).
Adiponectinwassigniﬁcantlyinverselyassociatedwiththe
number of risk factors (r =− 0.430, P = 0.0001) (Table 4).
4. Discussion
Inthepresentstudy,circulatingadiponectinwassigniﬁcantly
l o w e ri ns u b j e c t sw i t hd i ﬀerent degree of IGR compared
to subjects with normal glucose homeostasis. Furthermore
we conﬁrm previously observed positive correlations of adi-
ponectin with HDL and negative correlations with glucose,
HbA1c, triglycerides, insulin, and HOMA-IR and report an
inverse correlation with ALT. In multiple regression models
HbA1C as well as ALT was independent determinant of adi-
ponectin levels and explained 38.2% of variability in plasma
adiponectin levels.Additionally, adiponectin wassigniﬁcant-
ly lower in high-risk group than low-risk group and de-
creased concurrently with increased number of CVRFs.
Thus, hypoadiponectinemia is more intensively related to
glucose intolerance and CVRFs load than to adiposity.
The site and mechanism of adiponectin actions on glu-
cose metabolism remain unknown. Recent genome-wide
scans have mapped a diabetes susceptibility locus to chro-
mosome3q27,wheretheadiponectin gene(apM1)islocated
[12]. Evidence of an association between type 2 diabetes and
singlenucleotidepolymorphismsatpositions45and276and
in the proximal promoter and exon 3 of the adiponectin gene
has been also reported [11]. Furthermore, it has been shown
that circulating adiponectin levels are signiﬁcantly lower in
healthy ﬁrst-degree relatives of type 2 diabetic patients [13].
In our study, plasma adiponectin levels were signiﬁcantly
l o w e ri nb o t hI F Ga n dD Mg r o u p sc o m p a r e dt os u b j e c t s
withnormalglucosetolerance.Moreover,HbA1Clevelswere
independent determinant of circulating adiponectin. There-
fore, there is a scientiﬁc rationale that plasma adiponectin is
a target for future research in the treatment and prevention
of diabetes. We suggest that increase in adiponectin levels by
combination of lifestyle modiﬁcations and medications may
have a beneﬁcial eﬀect in patients with impaired glucose re-
gulation.
Our study conﬁrmed previously observed strong inverse
associations between low adiponectin levels and some of the
well-knownriskfactorsforatherosclerosis,suchaslowHDL-
cholesterol levels, hypertriglyceridemia, and insulin resis-
tance[14–16].Additionally,wefoundsigniﬁcantinversecor-
relation between adiponectin and ALT, a surrogate marker
for nonalcoholic fatty liver disease, which has recently been
considered as a predictor for development of type 2 diabetes
andmetabolicsyndrome[17–19].Theseﬁndingsclearlysup-
port the point of view that adiponectin may have an active
role in the pathogenesis of cardiovascular diseases.4 Experimental Diabetes Research
Table 3: Clinical characteristics of study patients by CVRFs load.
Variables Low-risk subjects
n = 52
High-risk subjects
n = 55 P value
Age 57.7 ±9.15 5 .2 ±10.8 0.200
Sex (M/F) 13 (25%) 27 (49%) 0.01
BMI 31.8 ±6.73 3 .7 ±6.2 0.135
CVRFs median (range) 2 (range 0–2) 3 (range 3–4) 0.002
Systolic blood pressure (mmHg) 128.1 ±18.0 137.9 ±18.2 0.006
Diastolic blood pressure (mmHg) 72.7 ±12.57 7 .7 ±11.1 0.032
Mean arterial pressure (mmHg) 94.7 ±14.29 9 .0 ±14.4 0.126
Fasting blood glucose (mg/dL) 93.7 ±19.0 128.2 ±45.8 0.0001
HBAIC (%) 5.7 ±0.66 .9 ±1.80 .0001
HDL-cholesterol (mg/dL) 56.5 ±16.14 5 .0 ±15.40 .0001
Triglycerides (mg/dL) 104.0 ±47.5 186.0 ±119.4 0.0001
Hs-CRP (mg/dL) 0.9 ±0.40 .9 ±1.1 0.408
Fasting insulin (IU/mL) 11.9 ±7.62 2 .6 ±17.4 0.0001
HOMA-IR 2.7 ±1.87 .0 ±4.5 0.0001
AST (mg/dL) 22.4 ±7.02 8 .0 ±14.3 0.011
ALT (mg/dL) 25.6 ±12.13 2 .6 ±23.6 0.204
Adiponectin (ng/mL) 13701.1 ±7051.5 6755.6 ±3492.2 0.0001
Table 4: Correlations between adiponectin levels and number of CVRFs.
Correlations CVRF’s Adiponectin
Spearman’s rho
CVRF’s
Correlation coeﬃcient 1.000 −0.430(∗∗)
Sig. (2-tailed) 0.0001
N 107 107
Adiponectin
Correlation coeﬃcient −0.430(∗∗) 1.000
Sig. (2-tailed) 0.0001
N 107 107
∗∗Correlation is signiﬁcant at the 0.01 level (2-tailed).
In the present study, no associations of adiponectin with
BMI have been found; however, other studies have been un-
able to detect associations between adiponectin and whole-
body fat mass and subcutaneous fat volume [20]. Neverthe-
less,anassociation betweenBMIandcirculatingadiponectin
levels has been reported by other authors [21, 22]. Although
we did not ﬁnd the associations of adiponectin with BMI as
well as diﬀerences in adiponectin levels between obese (BMI
≥30kg/m2) and nonobese study participants, the possibility
that the relatively small sample size in the present study
limited exploration of these potential correlations cannot be
excluded.
The present study observed strong associations between
a d i p o n e c t i nl e v e l sa n dg l u c o s et o l e r a n c es t a t u sa sw e l la s
number of cardiovascular risk factors. Thus, despite the fact
that adiponectin is highly speciﬁc to adipose tissue, hypo-
adiponectinemia is more intensively related to impaired glu-
cose regulation and CVRFs load than to adiposity. The ﬁnd-
ings of our study are in accordance with published data that
circulatingadiponectinlevelisastrongriskmarkerformeta-
bolic syndrome independent of measures of adiposity [15].
Moreover, decreased plasma adiponectin levels are inde-
pendently associated with the presence of coronary artery
disease in men even after adjustment for BMI [23]. Among
healthy men in the Health Professionals Follow-up Study,
a doubling of adiponectin levels was associated with a 30%
decreased risk for myocardial infarction after adjustment for
BMI, alcohol consumption, physical activity, diabetes, and
hypertension [24]. Similarly, among patients with type 1 and
type 2 diabetes mellitus, increased circulating adiponectin
levels were associated with a lower risk of coronary artery
disease after adjusting for standard risk factors [25, 26].
These combined ﬁndings indicate that adiponectin may have
a direct antiatherogenic role or mediate its eﬀects via obesi-
ty-independent mechanisms.
Thus, plasma adiponectin integrates with the cardiovas-
cular risk factors and is a potential target for research in
reducing morbidity and mortality of atherosclerotic disease.
Future research should focus on clinical endpoints such as
prevention of diabetes and reduction of cardiovascular mor-
bidity and mortality following adiponectin increase, as well
as the ability of adiponectin values to predict these out-
comes.Experimental Diabetes Research 5
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